Search
Xilio Therapeutics Inc
XLOAdd to Watchlist
8.360USD
-0.450-5.11%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
50.02MMarket Cap
LossP/E TTM
More Details of Xilio Therapeutics Inc Company
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
Xilio Therapeutics Inc Info
Ticker SymbolXLO
Company nameXilio Therapeutics Inc
IPO dateOct 22, 2021
CEORusso (Rene)
Number of employees64
Security typeOrdinary Share
Fiscal year-endOct 22
Address828 Winter Street
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone16174304680
Websitehttps://xiliotx.com/
Ticker SymbolXLO
IPO dateOct 22, 2021
CEORusso (Rene)
Company Executives of Xilio Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Director
Independent Director
10.00K
+50.00%
Dr. Rene Russo, Pharm.D.
Dr. Rene Russo, Pharm.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher (Chris) Frankenfield
Mr. Christopher (Chris) Frankenfield
Chief Financial Officer and Operating Officer
Chief Financial Officer and Operating Officer
--
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Robert W. (Rob) Ross, M.D.
Dr. Robert W. (Rob) Ross, M.D.
Independent Director
Independent Director
--
--
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Independent Director
Independent Director
--
--
Dr. Daniel J. Curran, M.D.
Dr. Daniel J. Curran, M.D.
Independent Director
Independent Director
--
--
Ms. Christina Rossi
Ms. Christina Rossi
Independent Director
Independent Director
--
--
Mr. Kevin Brennan
Mr. Kevin Brennan
Senior Vice President - Finance & Accounting
Senior Vice President - Finance & Accounting
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Director
Independent Director
10.00K
+50.00%
Dr. Rene Russo, Pharm.D.
Dr. Rene Russo, Pharm.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Christopher (Chris) Frankenfield
Mr. Christopher (Chris) Frankenfield
Chief Financial Officer and Operating Officer
Chief Financial Officer and Operating Officer
--
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Robert W. (Rob) Ross, M.D.
Dr. Robert W. (Rob) Ross, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
43.77M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gilead Sciences, Inc
10.87%
GKCC, LLC
8.36%
Frazier Life Sciences Management, L.P.
7.06%
AbbVie, Inc.
5.19%
Coastlands Capital LP
5.17%
Other
63.35%
Shareholders
Shareholders
Proportion
Gilead Sciences, Inc
10.87%
GKCC, LLC
8.36%
Frazier Life Sciences Management, L.P.
7.06%
AbbVie, Inc.
5.19%
Coastlands Capital LP
5.17%
Other
63.35%
Shareholder Types
Shareholders
Proportion
Corporation
27.95%
Hedge Fund
15.11%
Investment Advisor
9.64%
Private Equity
7.06%
Venture Capital
2.54%
Investment Advisor/Hedge Fund
1.05%
Individual Investor
0.63%
Research Firm
0.06%
Other
35.95%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q4
48
14.32M
28.99%
--
2026Q1
71
2.12M
35.46%
+872.72K
2025Q4
66
15.87M
23.50%
-2.47M
2025Q3
65
13.13M
25.34%
-6.35M
2025Q2
74
35.70M
68.94%
+3.82M
2025Q1
76
35.65M
68.85%
+3.77M
2024Q4
70
35.35M
73.19%
+8.60M
2024Q3
67
30.96M
73.92%
+4.31M
2024Q2
73
31.95M
83.81%
+2.44M
2024Q1
95
22.55M
67.42%
+68.86K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilead Sciences, Inc
650.39K
11.25%
--
--
Dec 31, 2025
GKCC, LLC
500.00K
8.65%
--
--
Jan 26, 2026
Frazier Life Sciences Management, L.P.
422.51K
7.31%
+422.51K
--
Dec 31, 2025
AbbVie, Inc.
310.56K
5.37%
+310.56K
--
Feb 11, 2025
Coastlands Capital LP
309.44K
5.35%
+309.44K
--
Dec 04, 2025
Point72 Asset Management, L.P.
285.71K
4.94%
+285.71K
--
Dec 31, 2025
Sio Capital Management, LLC
152.47K
2.64%
+152.47K
--
Dec 31, 2025
StemPoint Capital LP
145.00K
2.51%
+145.00K
--
Dec 31, 2025
Merck & Co Inc
105.98K
1.83%
--
--
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Mar 12, 2026
Merger
14→1
Date
Ex-dividend Date
Type
Ratio
Mar 12, 2026
Merger
14→1
